United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Monday, September 14th. The stock was sold at an average price of $504.12, for a total value of $4,789,140.00. Following the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $163,558,205.16. The trade was a 2.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

United Therapeutics Stock Down 0.5%

NASDAQ UTHR opened at $500.35 on Wednesday. United Therapeutics Corporation has a fifty-two week low of $397.00 and a fifty-two week high of $609.35. The business has a fifty day moving average of $518.75 and a 200-day moving average of $540.72. The stock has a market cap of $21.46 billion, a price-to-earnings ratio of 17.90, a price-to-earnings-growth ratio of 2.52 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same quarter last year, the company earned $6.41 earnings per share. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. As a group, analysts anticipate that United Therapeutics Corporation will post 26.21 EPS for the current year.

Analysts Set New Price Targets

UTHR has been the subject of a number of analyst reports. Bank of America cut their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. JPMorgan Chase & Co. lifted their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, Morgan Stanley set a $515.00 price target on United Therapeutics in a research note on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $646.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in UTHR. BlackRock Inc. purchased a new position in shares of United Therapeutics in the 2nd quarter worth about $2,868,735,000. Janus Henderson Group PLC increased its position in United Therapeutics by 8.9% during the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after purchasing an additional 70,829 shares in the last quarter. Jupiter Topco LLC acquired a new stake in United Therapeutics during the 2nd quarter worth approximately $450,140,000. Norges Bank purchased a new position in United Therapeutics in the fourth quarter valued at approximately $293,418,000. Finally, Swedbank AB raised its holdings in United Therapeutics by 0.7% in the first quarter. Swedbank AB now owns 327,122 shares of the biotechnology company’s stock valued at $193,977,000 after buying an additional 2,350 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.